GeneHealth - Your precision medicine

Geleophysic Dysplasia 2

Disease Details

Family Health Simplified

Buy Membership

Description: Geleophysic dysplasia 2 is a rare genetic disorder characterized by short stature, joint stiffness, heart valve abnormalities, and distinctive facial features.
Type: Geleophysic dysplasia 2 (GPHYSD2) is a rare genetic disorder characterized by short stature, short hands and feet, a "happy" facial appearance, and joint stiffness. The genetic transmission of GPHYSD2 is autosomal recessive, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to develop the disorder.
Signs And Symptoms: Geleophysic dysplasia 2 is a rare genetic disorder characterized by several distinct features. Signs and symptoms of this condition may include:

1. Short stature and short extremities
2. Facial abnormalities (including a broad nose, thin lips, and a round face)
3. Joint contractures, particularly affecting the fingers and toes
4. Tracheal stenosis, which can cause respiratory difficulties
5. Progressive cardiac involvement, such as heart valve abnormalities
6. Thickened skin

Affected individuals may also have a somewhat “happy” appearance, contributing to the term "geleophysic," which is derived from the Greek words for "happy" (gelios) and "appearance" (physic).
Prognosis: Geleophysic dysplasia 2 is a rare genetic disorder characterized by short stature, joint stiffness, a distinctive facial appearance, and often, heart and skeletal abnormalities. The prognosis can vary based on the severity of symptoms and associated complications. Early diagnosis and management are crucial to address symptoms and improve quality of life. Cardiovascular complications are a significant concern and can impact life expectancy if not appropriately managed. Close monitoring and a multidisciplinary approach to care are recommended. Treatment is symptomatic and supportive, focusing on managing heart, respiratory, and orthopedic issues.
Onset: Geleophysic dysplasia 2 typically has an onset in early childhood.
Prevalence: Geleophysic dysplasia 2 is an extremely rare genetic disorder, and there is limited information on its exact prevalence. Due to its rarity, precise prevalence data is not available, but it is recognized through only a small number of reported cases worldwide.
Epidemiology: Geleophysic dysplasia 2 (GD2) is an extremely rare genetic disorder. Due to its rarity, specific epidemiological data, including prevalence and incidence rates, are not well-documented in the scientific literature. It has been described in only a limited number of cases worldwide. The condition is usually inherited in an autosomal recessive manner, implicating mutations in the ADAMTSL2 gene.
Intractability: Geleophysic dysplasia 2 is a rare genetic disorder characterized by skeletal abnormalities, cardiac issues, and distinctive facial features. It is typically caused by mutations in the ADAMTSL2 gene. While there is currently no cure for the disease, management focuses on treating symptoms and complications, such as cardiac and respiratory issues. The condition is considered challenging to manage due to its severity and the range of complications, but comprehensive care and medical interventions can improve quality of life. Thus, it can be considered intractable in terms of a cure, but not necessarily untreatable in terms of symptom management.
Disease Severity: Geleophysic dysplasia 2 is a rare genetic disorder characterized by short stature, distinctive facial features, and progressive thickening of the skin and heart valves. Disease severity can vary but often includes significant complications such as cardiac and respiratory issues. Without proper management, it can be life-threatening.
Healthcare Professionals: Disease Ontology ID - DOID:0111726
Pathophysiology: Geleophysic dysplasia 2 is a rare genetic disorder. The pathophysiology involves mutations in the ADAMTSL2 gene, which encodes a protein involved in the extracellular matrix. These mutations disrupt normal tissue development and maintenance, leading to characteristic features such as short stature, short hands and feet, facial dysmorphisms, heart valve abnormalities, and joint stiffness.
Carrier Status: Carrier status for Geleophysic Dysplasia 2, also known as ADAMTSL2-related geleophysic dysplasia, involves being a carrier of a mutation in the ADAMTSL2 gene. Carriers typically do not show symptoms of the disease but can pass the mutated gene to their offspring.
Mechanism: Geleophysic dysplasia 2 (GPHYSD2) is a rare genetic disorder characterized by a distinctive combination of skeletal abnormalities, short stature, and facial features. The disorder is caused by mutations in the ADAMTSL2 gene, which plays a role in the formation and maintenance of elastic fibers in connective tissue.

Mechanism:
Mutations in the ADAMTSL2 gene lead to defective or insufficient production of the ADAMTS-like 2 protein. This protein is involved in the regulation of transforming growth factor-beta (TGF-β) signaling pathways, which are crucial for proper cellular growth, differentiation, and extracellular matrix formation. Altered TGF-β signaling due to defective ADAMTS-like 2 protein disrupts the normal development and maintenance of connective tissues and skeletal structures.

Molecular Mechanisms:
1. ADAMTSL2 gene mutations result in a non-functional or partially functional ADAMTS-like 2 protein.
2. Impaired ADAMTS-like 2 protein disrupts the regulation of TGF-β signaling, leading to abnormal extracellular matrix composition.
3. Disrupted TGF-β signaling affects normal cellular processes involved in skeletal development and maintenance.
4. The result is improper formation and maintenance of connective tissues, leading to the skeletal abnormalities and other symptoms observed in individuals with Geleophysic dysplasia 2.

Key features of GPHYSD2 include short stature, joint contractures, thickened skin, and characteristic facial features. Early diagnosis and supportive care can help manage some of the symptoms associated with this condition.
Treatment: Geleophysic dysplasia 2 is a rare genetic disorder with no specific cure. Treatment is generally supportive and symptomatic, focusing on managing complications related to the disease. This can include physical therapy, respiratory support, and surgical interventions to address issues such as heart valve abnormalities or skeletal deformities. Regular monitoring by a multidisciplinary team of specialists is often necessary to manage the various symptoms and complications effectively.
Compassionate Use Treatment: Geleophysic dysplasia 2 (GD2) is a rare genetic disorder primarily caused by mutations in the ADAMTSL2 gene. Currently, there are no established treatments or approved medications specifically for GD2. However, certain compassionate use, off-label, or experimental treatments might be considered under a healthcare provider's guidance.

1. **Compassionate Use**: This involves accessing investigational drugs outside clinical trials for patients with serious conditions. For GD2, compassionate use of specific investigational therapies targeting the underlying genetic or molecular defects might be explored.

2. **Off-label Treatments**: This can include the use of existing medications for symptoms or complications associated with GD2. For example, treatments addressing cardiac issues, respiratory problems, or joint stiffness may be utilized off-label.

3. **Experimental Treatments**: Clinical trials and research studies investigating potential therapies for genetic disorders may be options for patients. Genetic therapies, enzyme replacement therapies, or other novel approaches targeting similar connective tissue diseases could be under investigation.

Patients or caregivers should consult with a geneticist or specialized healthcare provider to explore these options, considering the specific clinical manifestations and severity of the disorder.
Lifestyle Recommendations: For Geleophysic Dysplasia 2, the following lifestyle recommendations may be considered to support overall well-being:

1. **Medical Monitoring:** Regular follow-ups with a healthcare team including geneticists, cardiologists, and orthopedic specialists.
2. **Physiotherapy:** Engaging in physiotherapy to maintain mobility and manage joint stiffness.
3. **Healthy Diet:** Ensuring a balanced diet to support general health and potentially reduce the impact of growth delays.
4. **Physical Activity:** Incorporating low-impact exercises suitable for maintaining joint function without imposing excessive strain.
5. **Respiratory Care:** Monitoring and managing potential respiratory issues, given the risk of airway obstruction.
6. **Psychosocial Support:** Providing psychological support to deal with any social and emotional challenges arising from the condition.

Consultation with a healthcare professional is essential to tailor these recommendations to individual needs.
Medication: Geleophysic dysplasia 2 is a rare genetic disorder, and there is currently no specific medication for its treatment. Management typically focuses on addressing the symptoms and complications associated with the condition. This can include supportive care, physical therapy, and surgical interventions if necessary. Genetic counseling is also recommended for affected families.
Repurposable Drugs: Geleophysic dysplasia 2 is a rare genetic disorder often caused by mutations in the ADAMTSL2 gene. Currently, no specific repurposed drugs are widely recognized for this condition. Management typically focuses on symptomatic treatment and supportive care. It is advisable to consult a specialist for current and personalized treatment options.
Metabolites: Geleophysic dysplasia 2 is a rare genetic disorder characterized by short stature, skeletal abnormalities, heart valve defects, and distinctive facial features. Specific data on metabolites associated with Geleophysic dysplasia 2 may not be extensively documented. To obtain detailed information on metabolic changes or biomarkers related to this condition, consulting a specialist in metabolic disorders or reviewing specific medical literature may be necessary.
Nutraceuticals: Geleophysic dysplasia 2 is a rare genetic disorder caused by mutations in the ADAMTSL2 gene. Currently, there are no specific nutraceuticals recommended for the treatment or management of this condition. Nutritional and supportive care should be tailored to each individual's symptoms and clinical needs, under the guidance of their healthcare provider.
Peptides: Geleophysic dysplasia 2 is a rare genetic disorder characterized by short stature, joint stiffness, and distinctive facial features. It is caused by mutations in the ADAMTSL2 gene. The term "peptides, nan" is unclear in this context. If you are referring to potential treatments or molecular aspects, peptides may be studied in various contexts, such as biomarker discovery or therapeutic targets, but there is no specific peptide treatment for this condition as of now. More precise information would be needed to give a detailed answer.